^
    1m
    REMASTER: A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis (clinicaltrials.gov)
    P3, N=1275, Not yet recruiting, Novartis Pharmaceuticals
    New P3 trial
    |
    Rhapsido (remibrutinib)
    1m
    A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines (clinicaltrials.gov)
    P3, N=364, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting | Trial completion date: Dec 2028 --> Aug 2028
    Enrollment closed • Trial completion date • Pan tumor
    |
    Rhapsido (remibrutinib)
    4ms
    A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impairment Compared to Matched Healthy Participants. (clinicaltrials.gov)
    P1, N=16, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rhapsido (remibrutinib)
    4ms
    Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. (clinicaltrials.gov)
    P3, N=360, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open • Head-to-Head
    |
    Rhapsido (remibrutinib) • Ocrevus (ocrelizumab)
    5ms
    RECLAIM: A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines (clinicaltrials.gov)
    P3, N=400, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rhapsido (remibrutinib) • Dupixent (dupilumab)
    6ms
    Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension. (clinicaltrials.gov)
    P3, N=470, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Rhapsido (remibrutinib)
    6ms
    A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impairment Compared to Matched Healthy Participants. (clinicaltrials.gov)
    P1, N=16, Not yet recruiting, Novartis Pharmaceuticals
    New P1 trial
    |
    Rhapsido (remibrutinib)
    7ms
    Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria (clinicaltrials.gov)
    P2, N=44, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rhapsido (remibrutinib)
    8ms
    24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up (clinicaltrials.gov)
    P3, N=100, Recruiting, Novartis Pharmaceuticals | Trial primary completion date: Nov 2025 --> Apr 2026
    Trial primary completion date
    |
    Rhapsido (remibrutinib)
    9ms
    Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts (clinicaltrials.gov)
    P2, N=76, Completed, Novartis Pharmaceuticals | Active, not recruiting --> Completed
    Trial completion
    |
    Rhapsido (remibrutinib)
    9ms
    Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria (clinicaltrials.gov)
    P2, N=44, Not yet recruiting, Novartis Pharmaceuticals
    New P2 trial
    |
    Rhapsido (remibrutinib)
    9ms
    RECHARGE 2: Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (clinicaltrials.gov)
    P3, N=555, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rhapsido (remibrutinib)